Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study.

BACKGROUND: In January, 2021, a vaccination campaign against COVID-19 was initiated with the rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines in Argentina. The objective of this study was to estimate vaccine effectiveness at reducing risk of SARS-CoV-2 infection and COVID-19 deaths in people older than 60 years. METHODS: In this test-negative, case-control, and retrospective longitudinal study done in Argentina, we evaluated the effectiveness of three vaccines (rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV) on SARS-CoV-2 infection and risk of death in people with RT-PCR confirmed COVID-19, using data from the National Surveillance System (SNVS 2.0). All individuals aged 60 years or older reported to SNVS 2.0 as being suspected to have COVID-19 who had disease status confirmed with RT-PCR were included in the study. Unvaccinated individuals could participate in any of the analyses. People with suspected COVID-19 who developed symptoms before the start of the implementation of the vaccination programme for their age group or district were excluded from the study. The odds ratio of SARS-CoV-2 infection was evaluated by logistic regression and the risk of death in individuals with RT-PCR confirmed COVID-19 was evaluated by proportional hazard regression models, adjusted for possible confounders: age at the time of the symptom onset date, sex, district of residence, epidemiological week corresponding to the symptom onset date, and history of COVID-19. The estimation of vaccine effectiveness to prevent death due to COVID-19 was done indirectly by combining infection and death estimates. In addition, we evaluated the effect of the first dose of viral vector vaccines across time. FINDINGS: From Jan 31, to Sept 14, 2021, 1 282 928 individuals were included, of whom 687 167 (53·6%) were in the rAd26-rAd5 analysis, 358 431 (27·6%) in the ChAdOx1 nCoV-19 analysis, and 237 330 (18·5%) in the BBIBP-CorV analysis. Vaccine effectiveness after two doses was high for all three vaccines, adjusted odds ratio 0·36 (95% CI 0·35-0·37) for rAd26-rAd5, 0·32 (0·31-0·33) for ChAdOx1 nCoV-19, and 0·56 (0·55-0·58) for BBIBP-CorV. After two doses, the effect on deaths was higher than that on risk of infection: adjusted hazard ratio 0·19 (95% CI 0·18-0·21) for rAd26-rAd5, 0·20 (0·18-0·22) for ChAdOx1 nCoV-19, and 0·27 (0·25-0·29) for BBIBP-CorV. The indirectly estimated effectiveness on deaths was 93·1% (95% CI 92·6-93·5) for rAd26-rAd5, 93·7% (93·2-94·3) for ChAdOx1 nCoV-19, and 85·0% (84·0-86·0) for BBIBP-CorV following two doses. First dose effect of viral vector vaccines remained stable over time. INTERPRETATION: The vaccines used in Argentina showed effectiveness in reducing infection and death by SARS-CoV-2 and COVID-19. FUNDING: None.

Epidemiology of Dengue in Argentina during the 2010/11 to 2019/20 Seasons: A Contribution to the Burden of Disease.

BACKGROUND: Dengue is an important public health problem in Argentina, as in many other countries. We reviewed and updated information on the dengue disease burden in Argentina over a 10-year period. METHODS: We conducted a retrospective descriptive study from 2010 to 2020 based on data from the National Health Surveillance System. The main outcomes included dengue cases, incidence rates, deaths, and serotype distribution by season, age group, and region. RESULTS: A total of 109,998 confirmed cases of dengue were reported. Seasonality stands out, prevailing during summer and autumn. Two main outbreaks (seasons 2015/16 and 2019/20), with increasing magnitude, were observed. The 2019/20 season showed the highest number of cases (58,731) and incidence rate (135/100,000). The Northeast region had the highest number of cases and incidence rate. In 2020, for the first time, autochthonous cases were registered in the Cuyo region. The only region with no autochthonous cases was the South. Adolescents and young adults showed the highest incidence rate. The case fatality rate for the period was 0.05%. Four serotypes circulated, but the predominant one was DEN-1 (78%). CONCLUSIONS: Dengue has been expanding temporally and spatially. Although the DEN-1 serotype widely predominated, the increasing circulation of other serotypes raises concerns regarding re-exposure and the severity of future cases. Understanding epidemiological trends is key to defining public prevention and control policies.

Severity of influenza illness by seasonal influenza vaccination status among hospitalised patients in four South American countries, 2013-19: a surveillance-based cohort study.

BACKGROUND: Although several studies have reported attenuated influenza illness following influenza vaccination, results have been inconsistent and have focused predominantly on adults in the USA. This study aimed to evaluate the severity of influenza illness by vaccination status in a broad range of influenza vaccine target groups across multiple South American countries. METHODS: We analysed data from four South American countries (Argentina, Brazil, Chile, and Paraguay) participating in REVELAC-i, a multicentre, test-negative design, vaccine effectiveness network including 41 sentinel hospitals. Individuals hospitalised at one of these centres with severe acute respiratory infection were tested for influenza by real-time RT-PCR, and were included in the analysis if they had complete information about their vaccination status and outcomes of their hospital stay. We used multivariable logistic regression weighted by inverse probability of vaccination and adjusted for antiviral use, duration of illness before admission, and calendar week, to calculate the adjusted odds ratios (aORs) of intensive care unit (ICU) admission and in-hospital death (and combinations of these outcomes) among influenza-positive patients by vaccination status for three target groups: young children (aged 6-24 months), adults (aged 18-64 years) with pre-existing health conditions, and older adults (aged ≥65 years). Survival curves were used to compare length of hospital stay by vaccination status in each target group. FINDINGS: 2747 patients hospitalised with PCR-confirmed influenza virus infection between Jan 1, 2013, and Dec 8, 2019, were included in the study: 649 children (70 [10·8%] fully vaccinated, 193 [29·7%] partially vaccinated) of whom 87 (13·4%) were admitted to ICU and 12 (1·8%) died in hospital; 520 adults with pre-existing medical conditions (118 [22·7%] vaccinated), of whom 139 (26·7%) were admitted to ICU and 55 (10·6%) died in hospital; and 1578 older adults (609 [38·6%] vaccinated), of whom 271 (17·2%) were admitted to ICU and 220 (13·9%) died in hospital. We observed earlier discharge among partially vaccinated children (adjusted hazard ratio 1·14 [95% CI 1·01-1·29]), fully vaccinated children (1·24 [1·04-1·47]), and vaccinated adults with pre-existing medical conditions (1·78 [1·18-2·69]) compared with their unvaccinated counterparts, but not among vaccinated older adults (0·82 [0·65-1·04]). Compared with unvaccinated individuals, lower odds of ICU admission were found for partially vaccinated children (aOR 0·64 [95% CI 0·44-0·92]) and fully vaccinated children (0·52 [0·28-0·98]), but not for adults with pre-existing conditions (1·25 [0·93-1·67]) or older adults (0·88 [0·72-1·08]). Lower odds of in-hospital death (0·62 [0·50-0·78]) were found in vaccinated versus unvaccinated older adults, with or without ICU admission, but did not differ significantly in partially vaccinated (1·35 [0·57-3·20]) or fully vaccinated young children (0·88 [0·16-4·82]) or adults with pre-existing medical conditions (1·09 [0·73-1·63]) compared with the respective unvaccinated patient groups. INTERPRETATION: Influenza vaccination was associated with illness attenuation among those hospitalised with influenza, although results differed by vaccine target group. These findings might suggest that attenuation of disease severity might be specific to certain target groups, seasons, or settings. FUNDING: US Centers for Disease Control and Prevention. TRANSLATIONS: For the Spanish and Portuguese translations of the abstract see Supplementary Materials section.

Effectiveness of mRNA-1273, BNT162b2, and BBIBP-CorV vaccines against infection and mortality in children in Argentina, during predominance of delta and omicron covid-19 variants: test negative, case-control study.

OBJECTIVE: To estimate the effectiveness of a two dose vaccine schedule (mRNA-1273, BNT162b2, and BBIBP-CorV) against SARS-CoV-2 infection and covid-19 related death and short term waning of immunity in children (3-11 years old) and adolescents (12-17 years old) during periods of delta and omicron variant predominance in Argentina. DESIGN: Test negative, case-control study. SETTING: Database of the National Surveillance System and the Nominalized Federal Vaccination Registry of Argentina. PARTICIPANTS: 844 460 children and adolescents without previous SARS-CoV-2 infection eligible to receive primary vaccination schedule who were tested for SARS-CoV-2 by polymerase chain reaction or rapid antigen test from September 2021 to April 2022. After matching with their corresponding controls, 139 321 (60.3%) of 231 181 cases remained for analysis. EXPOSURES: Two dose mRNA-1273, BNT162b2, and BBIBP-CorV vaccination schedule. MAIN OUTCOME MEASURES: SARS-CoV-2 infection and covid-19 related death. Conditional logistic regression was used to estimate the odds of SARS-CoV-2 infection among two dose vaccinated and unvaccinated participants. Vaccine effectiveness was estimated as (1-odds ratio)×100%. RESULTS: Estimated vaccine effectiveness against SARS-CoV-2 infection was 61.2% (95% confidence interval 56.4% to 65.5%) in children and 66.8% (63.9% to 69.5%) in adolescents during the delta dominant period and 15.9% (13.2% to 18.6%) and 26.0% (23.2% to 28.8%), respectively, when omicron was dominant. Vaccine effectiveness declined over time, especially during the omicron period, from 37.6% (34.2% to 40.8%) at 15-30 days after vaccination to 2.0% (1.8% to 5.6%) after ≥60 days in children and from 55.8% (52.4% to 59.0%) to 12.4% (8.6% to 16.1%) in adolescents.Vaccine effectiveness against death related to SARS-CoV-2 infection during omicron predominance was 66.9% (6.4% to 89.8%) in children and 97.6% (81.0% to 99.7%) in adolescents. CONCLUSIONS: Vaccine effectiveness in preventing mortality remained high in children and adolescents regardless of the circulating variant. Vaccine effectiveness in preventing SARS-CoV-2 infection in the short term after vaccination was lower during omicron predominance and decreasing sharply over time. TRIAL REGISTRATION: National Registry of Health Research IS003720.

Timing of respiratory syncytial virus and influenza epidemic activity in five regions of Argentina, 2007-2016.

BACKGROUND: Within-country differences in the timing of RSV and influenza epidemics have not been assessed in Argentina, the eighth largest country in the world by area. OBJECTIVE: We aimed to compare seasonality for RSV and influenza both nationally and in each of the five regions to inform Argentina's prevention and treatment guidelines. METHOD: The Argentine National Laboratories and Health Institutes Administration collected respiratory specimens from clinical practices, outbreak investigations, and respiratory virus surveillance in 2007-2016; these were tested using immunofluorescence or RT-PCR techniques. We calculated weekly percent positive (PP) and defined season onset as >2 consecutive weeks when PP exceeded the annual mean for the respective year and region. Median season measures (onset, offset and peak) and the established mean method were calculated for each virus. RESULTS: An annual median 59 396 specimens were tested for RSV and 60 931 for influenza; 21-29% tested positive for RSV and 2-7% for influenza. National RSV activity began in April; region-specific start weeks varied by 7 weeks. Duration of RSV activity did not vary widely by region (16-18 weeks in duration). National influenza activity started in June; region-specific start weeks varied by 3 weeks. Duration of influenza epidemic activity varied more by region than that of RSV (7-13 weeks in duration). CONCLUSION: In Argentina, RSV and influenza activity overlapped during the winter months. RSV season tended to begin prior to the influenza season, and showed more variation in start week by region. Influenza seasons tended to vary more in duration than RSV seasons.

Is autumn the key for dengue epidemics in non endemic regions? The case of Argentina.

BACKGROUND: Dengue is a major and rapidly increasing public health problem. In Argentina, the southern extreme of its distribution in the Americas, epidemic transmission takes place during the warm season. Since its re-emergence in 1998 two major outbreaks have occurred, the biggest during 2016. To identify the environmental factors that trigger epidemic events, we analyzed the occurrence and magnitude of dengue outbreaks in time and space at different scales in association with climatic, geographic and demographic variables and number of cases in endemic neighboring countries. METHODS: Information on dengue cases was obtained from dengue notifications reported in the National Health Surveillance System. The resulting database was analyzed by Generalized Linear Mixed Models (GLMM) under three methodological approaches to: identify in which years the most important outbreaks occurred in association with environmental variables and propose a risk estimation for future epidemics (temporal approach); characterize which variables explain the occurrence of local outbreaks through time (spatio-temporal approach); and select the environmental drivers of the geographical distribution of dengue positive districts during 2016 (spatial approach). RESULTS: Within the temporal approach, the number of dengue cases country-wide between 2009 and 2016 was positively associated with the number of dengue cases in bordering endemic countries and negatively with the days necessary for transmission (DNT) during the previous autumn in the central region of the country. Annual epidemic intensity in the period between 1999-2016 was associated with DNT during previous autumn and winter. Regarding the spatio-temporal approach, dengue cases within a district were also associated with mild conditions in the previous autumn along with the number of dengue cases in neighboring countries. As for the spatial approach, the best model for the occurrence of two or more dengue cases per district included autumn minimum temperature and human population as fixed factors, and the province as a grouping variable. Explanatory power of all models was high, in the range 57-95%. DISCUSSION: Given the epidemic nature of dengue in Argentina, virus pressure from endemic neighboring countries along with climatic conditions are crucial to explain disease dynamics. In the three methodological approaches, temperature conditions during autumn were best associated with dengue patterns. We propose that mild autumns represent an advantage for mosquito vector populations and that, in temperate regions, this advantage manifests as a larger egg bank from which the adult population will re-emerge in spring. This may constitute a valuable anticipating tool for high transmission risk events.

All-cause excess mortality during the COVID-19 pandemic in Argentina, 2020 / Exceso de mortalidad por todas las causas en el contexto de la pandemia de covid-19 en argentina, 2020

RESUMEN INTRODUCCIÓN: La vigilancia del exceso de mortalidad (EM) por todas las causas puede ser utilizada para evaluar la magnitud del impacto de la pandemia de la enfermedad por el coronavirus 2019 (COVID-19, por sus siglas en inglés). El objetivo de este estudio fue calcular el EM en Argentina durante 2020 y compararlo con las muertes por COVID-19 notificadas en el Sistema Nacional de Vigilancia de la Salud (SNVS). MÉTODOS: Se realizó un estudio descriptivo, en el que se analizaron las series de defunciones por todas las causas de los períodos 2015-2019 y 2020, y las muertes por COVID-19 notificadas al SNVS durante 2020. El EM se estableció como la diferencia entre el número de defunciones por todas las causas del año 2020 y el umbral de alerta (percentil 75 de los datos históricos). Se calculó la proporción de muertes en exceso no explicadas por los casos confirmados de COVID-19 fallecidos. RESULTADOS: En 2020 el EM en Argentina fue de 10,6% (36 306 muertes sobre el umbral). En el primer semestre no hubo exceso, las muertes observadas se encontraron por debajo del límite inferior esperado; en el segundo semestre fue de 25,6% por encima del umbral. Se notificaron 45 568 fallecidos por COVID-19 mediante el SNVS. DISCUSIÓN: Los valores de mortalidad concuerdan con la evolución de la pandemia en el país. El sistema de notificación de fallecidos por COVID-19 es robusto debido al aporte de una amplia red y al cotejo con otras fuentes oficiales para completar la información en el SNVS.

ABSTRACT INTRODUCTION: All-cause excess mortality (EM) surveillance can be used to assess the impact of the COVID-19 pandemic. The aim of this study was to estimate the EM in Argentina in 2020 and compare it with the deaths from COVID-19 reported in the National Health Surveillance System (SNVS). METHODS: A descriptive study was conducted based on the analysis of all-cause mortality series for the period 2015-2019,2020 and confirmed COVID-19 deaths during 2020 in Argentina. The EM was calculated as the difference between the number of deaths in 2020 and the alert threshold (75th percentile of historical data). The proportion of excess deaths not explained by deaths reported by COVID-19 in the surveillance system was calculated. RESULTS: EM in Argentina in 2020 was 10.6% (36306 deaths above the threshold). In the first half of the year there was no excess, deaths were below the expected lower limit; in the second half of the year it was 25.6% above the threshold. A total of45568 COVID-19 deaths were reported to the SNVS. DISCUSSION: Mortality values are in accordance with the evolution of the pandemic in the country. The COVID-19 death reporting system is robust due to the contribution of a wide notification network and the cross-checking with other official sources to complete the information in the SNVS.

Exceso de mortalidad por todas las causas en el contexto de la pandemia del COVID-19 en Argentina, 2020 / All-cause excess mortality during the COVID-19 pandemic in Argentina, 2020

INTRODUCCIÓN: La vigilancia del exceso de mortalidad (EM) por todas las causas puede ser utilizada para evaluar la magnitud del impacto de la pandemia de la enfermedad por el coronavirus 2019 (COVID-19, por sus siglas en inglés). El objetivo de este estudio fue calcular el EM en Argentina durante 2020 y compararlo con las muertes por COVID-19 notificadas en el Sistema Nacional de Vigilancia de la Salud (SNVS). MÉTODOS: Se realizó un estudio descriptivo, en el que se analizaron las series de defunciones por todas las causas de los períodos 2015-2019 y 2020, y las muertes por COVID-19 notificadas al SNVS durante 2020. El EM se estableció como la diferencia entre el número de defunciones por todas las causas del año 2020 y el umbral de alerta (percentil 75 de los datos históricos). Se calculó la proporción de muertes en exceso no explicadas por los casos confirmados de COVID-19 fallecidos. RESULTADOS: En 2020 el EM en Argentina fue de 10,6% (36 306 muertes sobre el umbral). En el primer semestre no hubo exceso, las muertes observadas se encontraron por debajo del límite inferior esperado; en el segundo semestre fue de 25,6% por encima del umbral. Se notificaron 45 568 fallecidos por COVID-19 mediante el SNVS. DISCUSIÓN: Los valores de mortalidad concuerdan con la evolución de la pandemia en el país. El sistema de notificación de fallecidos por COVID-19 es robusto debido al aporte de una amplia red y al cotejo con otras fuentes oficiales para completar la información en el SNVS

Elaboración de criterios epidemiológicos para estratificar por departamento poblacional de dengue grave / Development of Epidemiological Criteria to stratify by Department the Population Risk of Severe Dengue

: INTRODUCCIÓN: En Argentina desde 1998 ocurrieron brotes de dengue todos los años excepto 2001 y 2005 en diferentes áreas, en 15 jurisdicciones, con identificación de los 4 serotipos. El objetivo de este estudio fue identificar poblaciones con mayor riesgo de desarrollar formas graves de la enfermedad como insumo para la posible introducción de una estrategia de prevención. METODOS: Se realizó un estudio retrospectivo descriptivo de los casos de dengue confirmados autóctonos a partir de publicaciones oficiales, notificaciones al SNVS e información aportada por las áreas de epidemiología provinciales. Se elaboró una estratificación del riesgo de dengue grave por departamento para el período 1998-2018. RESULTADOS: Se elaboraron 5 criterios de estratificación de riesgo: registro de casos autóctonos en al menos 2 de los 5 cinco últimos años, registro de 2 o más serotipos causantes del 10% o más de los casos cada uno, incidencia acumulada mayor a 500 casos por 100 mil habitantes, incidencia acumulada mayor a 5 casos por mil menores de 15 años y registro de casos graves o fallecidos. Se obtuvieron 60 departamentos con 1 criterio, 19 con 2, 8 con 3, 4 con 4, 1 con 5 y 129 no cumplieron criterios. DISCUSION: Solo 13 departamentos sumaron 3 criterios o más, resultado del predominio de DENV-1, la baja incidencia en menores de 15 años y el bajo número de casos graves y fatales. La estratificación del riesgo poblacional con criterios de registro sistemático se orienta a obtener una herramienta de evaluación de los escenarios de dengue que puedan presentarse en el futuro.

Epidemiological situation of pertussis and strategies to control it: Argentina, 2002-2011.

INTRODUCTION: Pertussis is a challenge for public health. OBJECTIVES: To describe pertussis-related morbidity and mortality and immunization coverage for the 2002-2011 period, profile of cases for 2011, and control strategies implemented by the Ministry of Health (MoH) of Argentina. METHODS: Descriptive, epidemiological surveillance study. Morbidity data were obtained from the National Health Surveillance System, while mortality data were obtained from the MoH's Health Statistics and Information Department and official jurisdictional reports. Administrative immunization coverage was used based on the data provided by the MoH's jurisdictions. The Epi Info software, version 7.1.2, was used for analysis. RESULTS: The number of reported cases of pertussis increased between 2002 and 2011, reaching its peak in 2011: an incidence of 16 x 100 000 inhabitants, and 76 deaths. Most deaths occurred in infants younger than 1 year old. Immunization coverage achieved at a national level with the third dose and the dose administered at the time of starting primary education was >90%, while the coverage achieved with the first booster dose was 80%-90%. In 2011, 2821 confirmed cases were reported (incidence of 7 x 100 000 inhabitants): 84% in infants <1 year old; 76 deaths: 97% in infants <1 year old (60.5% in infants <2 months old). Among the strategies that were deployed, a total of 906 clinical nodes and 405 laboratory nodes were consolidated; the use of the polymerase chain reaction as a diagnostic method and the differential classification of cases were implemented, and additional vaccine doses were administered. CONCLUSIONS: The number of pertussis cases increased between 2002 and 2011; the highest morbidity and mortality occurred in infants younger than 1 year old; immunization coverage reached 80%-90%. . The highest number of pertussis-related deaths was recorded in 2011. The MoH strengthened the epidemiological surveillance and set guidelines for control measures.

[Rotavirus epidemiology and surveillance in Argentina: 2009-2011]. / Vigilancia epidemiológica de rotavirus en la Argentina: 2009-2011.

It has been estimated that in Argentina, rotavirus causes approximately 80,000 to 100,000 clinic consultations annually and is responsible for 40% of acute diarrhea related hospital admissions in children under 5 years. In this study, national rotavirus surveillance data from 2009-2011 was consulted to asses prevalence, seasonality, age-group distribution as well as the national and regional genotypes circulating. It is essential to get deeper insight into the epidemiology and burden of rotavirus diarrhea for design of strategies and health interventions in order to prevent and control high impact human diseases.

Epidemiología de las arbovirosis emergentes en las Américas con foco en la Argentina / Epidemiology of the emerging arboviruses in the Americas with focus in Argentina

El presente trabajo tiene por objetivo brindar una síntesis de la situa-ción epidemiológica en las Américas de dengue, chikungunya y Zika, particularizando en la situación argentina. La revisión se basó en la lite-ratura científica tanto como en los reportes de organismos oficiales na-cionales e internacionales.El aumento de la incidencia, severidad y letalidad de dengue; la exten-sión de la epidemia de chikungunya a 46 países en 3 años con más de 2,3 millones de casos notificados,la emergencia del virus del Zika y su asociación con el aumento inusitado de casos de microcefalias y otras malformaciones cerebrales, así como el aumento de síndromes neuro-lógicos como Guillain-Barré en varios países de la región, evidencian que las arbovirosis emergentes en América constituyen grandes y com-plejos problemas para la salud pública de los ameri-canos.La situación en Argentina en los últimos años obli-ga a suponer que brotes de una o varias de estas ar-bovirosis a mayor escala pueden darse en el futuro.Por lo tanto será necesario tener en cuenta esta in-formación para: fortalecer las acciones de preven-ción y control de las enfermedades transmitidas por Aedes en el país; fortalecer las capacidades de los servicios de salud para la atención de la enferme-dad aguda como de sus complicaciones, formas gra-ves y secuelas; fortalecer los sistemas de vigilancia para un adecuado seguimiento de la situación epide-miológica.

The purpose of this paper is to provide a synthesis of the epidemiological situation in the Americas of dengue, chikungunya and Zika, particularizing in the Argentine situation. The review was based on the scientific literature as well as on the reports of national and international official organizations.Increased incidence, severity and lethality of dengue; the spread of the chikungunya epidemic to 46 countries in 3 years with more than 2.3 million cases reported, the emergence of the Zika virus and its association with the unusual increase in cases of microcephaly and other brain malformations, as well as the increase in neurological syndromes such as Guillain-Barré in several countries of the region, evidence that emerging arboviruses in America constitute a large and complex problems for the public health of Americans.The situation in Argentina in recent years forces one to assume that outbreaks of one or more of these arboviruses a mayor stairs may occur in the future.Therefore, it will be necessary to take this information into account in order to: strengthen the actions of prevention and control of diseases transmitted by Aedes in the country; strengthen the capacities of health services for the treatment of acute illness as well as its complications, severe forms and sequelae; strengthen surveillance systems for adequate monitoring of the epidemiological situation

Situación epidemiológica de coqueluche y estrategias para su control: Argentina, 2002-2011 / Epidemiological situation of pertussis and strategies to control it: Argentina, 2002-2011

Introducción. Coqueluche constituye un problema de salud pública. Objetivos: Describir la morbimortalidad y coberturas de vacunación entre 2002 y 2011, el perfil de los casos de 2011 y las estrategias de control implementadas por el Ministerio de Salud (MSN). Métodos. Estudio descriptivo de vigilancia epidemiológica. Los datos de morbilidad se tomaron del Sistema Nacional de Vigilancia, y los de mortalidad, de la Dirección de Estadística e Información en Salud del MSN y de los informes oficiales de las jurisdicciones. Se utilizó la cobertura administrativa de vacunación a partir de datos provistos por las jurisdicciones al MSN. Se analizó con Epiinfo 7.1.2. Resultados. Entre 2002 y 2011, la notificación de casos de coqueluche y de fallecimientos se incrementó y alcanzó los mayores valores en 2011: tasa de 16 x 100 000 habitantes y 76 fallecidos. Las muertes ocurrieron mayoritariamente en <1 año y las coberturas nacionales de vacunación para 3ra dosis e ingreso escolar fueron >90% y para el primer refuerzo, 80-90%. En 2011, se notificaron 2821 casos confirmados (incidencia 7 x 100 000 hab.): 84% <1 año; 76 fallecidos: 97% <1 año (60,5% <2 meses). Entre las estrategias implementadas, se consolidaron 906 nodos clínicos y 405 de laboratorio; se implementaron la reacción en cadena de la polimerasa como método diagnóstico y la clasificación diferencial de los casos, y se incorporaron dosis adicionales de vacunación. Conclusiones . Entre 2002 y 2011, aumentaron los casos de coqueluche; la mayor morbimortalidad fue en <1 año, con coberturas de vacunación de 80 y 90%. . El mayor número de fallecidos por coqueluche fue en el año 2011. . El MSN fortaleció la vigilancia epidemiológica y orientó las medidas de control.

Introduction. Pertussis is a challenge for public health. Objectives: To describe pertussis-related morbidity and mortality and immunization coverage for the 2002-2011 period, profile of cases for 2011, and control strategies implemented by the Ministry of Health (MoH) of Argentina. Methods. Descriptive, epidemiological surveillance study. Morbidity data were obtained from the National Health Surveillance System, while mortality data were obtained from the MoH's Health Statistics and Information Department and official jurisdictional reports. Administrative immunization coverage was used based on the data provided by the MoH's jurisdictions. The Epi Info software, version 7.1.2, was used for analysis. Results. The number of reported cases of pertussis increased between 2002 and 2011, reaching its peak in 2011: an incidence of 16 x 100 000 inhabitants, and 76 deaths. Most deaths occurred in infants younger than 1 year old. Immunization coverage achieved at a national level with the third dose and the dose administered at the time of starting primary education was >90%, while the coverage achieved with the first booster dose was 80%-90%. In 2011, 2821 confirmed cases were reported (incidence of 7 x 100 000 inhabitants): 84% in infants <1 year old; 76 deaths: 97% in infants <1 year old (60.5% in infants <2 months old). Among the strategies that were deployed, a total of 906 clinical nodes and 405 laboratory nodes were consolidated; the use of the polymerase chain reaction as a diagnostic method and the differential classification of cases were implemented, and additional vaccine doses were administered. Conclusions . The number of pertussis cases increased between2002 and 2011; the highest morbidity and mortality occurred ininfants younger than 1 year old; immunization coverage reached 80%-90%. . The highest number of pertussis-related deaths was recorded in 2011. . The MoH strengthened the epidemiological surveillance and set guidelines for control measures.

Situación epidemiológica de coqueluche y estrategias para su control: Argentina, 2002-2011 / Epidemiological situation of pertussis and strategies to control it: Argentina, 2002-2011

Introducción. Coqueluche constituye un problema de salud pública. Objetivos: Describir la morbimortalidad y coberturas de vacunación entre 2002 y 2011, el perfil de los casos de 2011 y las estrategias de control implementadas por el Ministerio de Salud (MSN). Métodos. Estudio descriptivo de vigilancia epidemiológica. Los datos de morbilidad se tomaron del Sistema Nacional de Vigilancia, y los de mortalidad, de la Dirección de Estadística e Información en Salud del MSN y de los informes oficiales de las jurisdicciones. Se utilizó la cobertura administrativa de vacunación a partir de datos provistos por las jurisdicciones al MSN. Se analizó con Epiinfo 7.1.2. Resultados. Entre 2002 y 2011, la notificación de casos de coqueluche y de fallecimientos se incrementó y alcanzó los mayores valores en 2011: tasa de 16 x 100 000 habitantes y 76 fallecidos. Las muertes ocurrieron mayoritariamente en <1 año y las coberturas nacionales de vacunación para 3ra dosis e ingreso escolar fueron >90% y para el primer refuerzo, 80-90%. En 2011, se notificaron 2821 casos confirmados (incidencia 7 x 100 000 hab.): 84% <1 año; 76 fallecidos: 97% <1 año (60,5% <2 meses). Entre las estrategias implementadas, se consolidaron 906 nodos clínicos y 405 de laboratorio; se implementaron la reacción en cadena de la polimerasa como método diagnóstico y la clasificación diferencial de los casos, y se incorporaron dosis adicionales de vacunación. Conclusiones . Entre 2002 y 2011, aumentaron los casos de coqueluche; la mayor morbimortalidad fue en <1 año, con coberturas de vacunación de 80 y 90%. . El mayor número de fallecidos por coqueluche fue en el año 2011. . El MSN fortaleció la vigilancia epidemiológica y orientó las medidas de control.(AU)

Introduction. Pertussis is a challenge for public health. Objectives: To describe pertussis-related morbidity and mortality and immunization coverage for the 2002-2011 period, profile of cases for 2011, and control strategies implemented by the Ministry of Health (MoH) of Argentina. Methods. Descriptive, epidemiological surveillance study. Morbidity data were obtained from the National Health Surveillance System, while mortality data were obtained from the MoHs Health Statistics and Information Department and official jurisdictional reports. Administrative immunization coverage was used based on the data provided by the MoHs jurisdictions. The Epi Info software, version 7.1.2, was used for analysis. Results. The number of reported cases of pertussis increased between 2002 and 2011, reaching its peak in 2011: an incidence of 16 x 100 000 inhabitants, and 76 deaths. Most deaths occurred in infants younger than 1 year old. Immunization coverage achieved at a national level with the third dose and the dose administered at the time of starting primary education was >90%, while the coverage achieved with the first booster dose was 80%-90%. In 2011, 2821 confirmed cases were reported (incidence of 7 x 100 000 inhabitants): 84% in infants <1 year old; 76 deaths: 97% in infants <1 year old (60.5% in infants <2 months old). Among the strategies that were deployed, a total of 906 clinical nodes and 405 laboratory nodes were consolidated; the use of the polymerase chain reaction as a diagnostic method and the differential classification of cases were implemented, and additional vaccine doses were administered. Conclusions . The number of pertussis cases increased between2002 and 2011; the highest morbidity and mortality occurred ininfants younger than 1 year old; immunization coverage reached 80%-90%. . The highest number of pertussis-related deaths was recorded in 2011. . The MoH strengthened the epidemiological surveillance and set guidelines for control measures.(AU)

Vigilancia epidemiológica de rotavirus en la Argentina: 2009-2011 / Rotavirus epidemiology and surveillance in Argentina: 2009-2011

Se estima que, en la Argentina, rotavirus produce entre 80 000 y 100 000 consultas médicas por año y es responsable del 40% de las internaciones por diarrea aguda en los menores de 5 años. El objetivo del presente trabajo es analizar los datos del período 2009-2011 en relación con la vigilancia nacional de rotavirus. Se estudió la prevalencia y distribución según el grupo etario, la frecuencia temporal y los genotipos circulantes. Resulta fundamental conocer la epidemiología y la carga de esta enfermedad para el diseño de estrategias e intervenciones en salud con el propósito de prevenir y controlar las enfermedades que tienen un alto impacto en la población.

It has been estimated that in Argentina, rotavirus causes approximately 80 000 to 100 000 clinic consultations annually and is responsible for 40% of acute diarrhea related hospital admissions in children under 5 years. In this study, national rotavirus surveillance data from 2009-2011 was consulted to asses prevalence, seasonality, agegroup distribution as well as the national and regional genotypes circulating. It is essential to get deeper insight into the epidemiology and burden of rotavirus diarrhea for design of strategies and health interventions in order to prevent and control high impact human diseases.

Vigilancia epidemiológica de rotavirus en la Argentina: 2009-2011 / Rotavirus epidemiology and surveillance in Argentina: 2009-2011

Se estima que, en la Argentina, rotavirus produce entre 80 000 y 100 000 consultas médicas por año y es responsable del 40% de las internaciones por diarrea aguda en los menores de 5 años. El objetivo del presente trabajo es analizar los datos del período 2009-2011 en relación con la vigilancia nacional de rotavirus. Se estudió la prevalencia y distribución según el grupo etario, la frecuencia temporal y los genotipos circulantes. Resulta fundamental conocer la epidemiología y la carga de esta enfermedad para el diseño de estrategias e intervenciones en salud con el propósito de prevenir y controlar las enfermedades que tienen un alto impacto en la población.(AU)

It has been estimated that in Argentina, rotavirus causes approximately 80 000 to 100 000 clinic consultations annually and is responsible for 40% of acute diarrhea related hospital admissions in children under 5 years. In this study, national rotavirus surveillance data from 2009-2011 was consulted to asses prevalence, seasonality, agegroup distribution as well as the national and regional genotypes circulating. It is essential to get deeper insight into the epidemiology and burden of rotavirus diarrhea for design of strategies and health interventions in order to prevent and control high impact human diseases.(AU)

Legionelosis: Recomendaciones para la prevención, la vigilancia epidemiológica y el control de casos y brotes / Legionellosis: Recommendations for prevention, epidemiological surveillance and control of cases and outbreaks

La enfermedad de los legionarios es un importante problema de salud pública particularmente por su frecuente presentación en forma de brotes, tanto comunitarios como nosocomiales, y por su letalidad, especialmente en personas de edad avanzada o con otras enfermedades. La notificación oportuna de casos y/o brotes de enfermedad y la investigación epidemiológica permiten la identificación de la/s fuentes de exposición y la adopción de medidas de prevención y control adecuadas. Las infecciones por Legionella son más frecuentes entre adultos mayores de 50 años, hombres, fumadores y huéspedes inmunocomprometidos o con ciertas enfermedades crónicas subyacentes. La infección en niñas/os es rara, con ≤ 1% de los casos de neumonía causada por Legionella, y puede ser asintomática o leve y no detectada. La Legionella puede multiplicarse si el agua no es tratada de manera adecuada o si los sistemas de agua no son mantenidos adecuadamente.

Guía de vigilancia epidemiológica y recomendaciones para la prevención y diagnóstico de las infecciones respiratorias agudas en Argentina / Epidemiological surveillance guide and recommendations for the prevention and diagnosis of acute respiratory infections in Argentina

En este documento se presenta las recomendaciones para el año 2018 con relación a la vigilancia de las infecciones respiratorias agudas (IRAs), recomendaciones de vacunación, diagnóstico etiológico, el uso de antivirales para Influenza e información a la población. Contó con la participación de las áreas del Ministerio de Salud de la Nación involucradas Dirección Nacional de Epidemiología y Análisis de Situación de Salud, Dirección de Maternidad e Infancia, Laboratorio Nacional de Referencia de Virus Respiratorios del INEI-ANLIS, Dirección de Control de Enfermedades Inmunoprevenibles.

Vigilancia epidemiológica de rotavirus en la Argentina: 2009-2011. / [Rotavirus epidemiology and surveillance in Argentina: 2009-2011].

It has been estimated that in Argentina, rotavirus causes approximately 80,000 to 100,000 clinic consultations annually and is responsible for 40

of acute diarrhea related hospital admissions in children under 5 years. In this study, national rotavirus surveillance data from 2009-2011 was consulted to asses prevalence, seasonality, age-group distribution as well as the national and regional genotypes circulating. It is essential to get deeper insight into the epidemiology and burden of rotavirus diarrhea for design of strategies and health interventions in order to prevent and control high impact human diseases.

Epidemiological situation of pertussis and strategies to control it: Argentina, 2002-2011. / Epidemiological situation of pertussis and strategies to control it: Argentina, 2002-2011.

INTRODUCTION: Pertussis is a challenge for public health. OBJECTIVES: To describe pertussis-related morbidity and mortality and immunization coverage for the 2002-2011 period, profile of cases for 2011, and control strategies implemented by the Ministry of Health (MoH) of Argentina. METHODS: Descriptive, epidemiological surveillance study. Morbidity data were obtained from the National Health Surveillance System, while mortality data were obtained from the MoHs Health Statistics and Information Department and official jurisdictional reports. Administrative immunization coverage was used based on the data provided by the MoHs jurisdictions. The Epi Info software, version 7.1.2, was used for analysis. RESULTS: The number of reported cases of pertussis increased between 2002 and 2011, reaching its peak in 2011: an incidence of 16 x 100 000 inhabitants, and 76 deaths. Most deaths occurred in infants younger than 1 year old. Immunization coverage achieved at a national level with the third dose and the dose administered at the time of starting primary education was >90

, while the coverage achieved with the first booster dose was 80

-90

. In 2011, 2821 confirmed cases were reported (incidence of 7 x 100 000 inhabitants): 84

in infants <1 year old; 76 deaths: 97

in infants <1 year old (60.5

in infants <2 months old). Among the strategies that were deployed, a total of 906 clinical nodes and 405 laboratory nodes were consolidated; the use of the polymerase chain reaction as a diagnostic method and the differential classification of cases were implemented, and additional vaccine doses were administered. CONCLUSIONS: The number of pertussis cases increased between 2002 and 2011; the highest morbidity and mortality occurred in infants younger than 1 year old; immunization coverage reached 80

-90

. . The highest number of pertussis-related deaths was recorded in 2011. The MoH strengthened the epidemiological surveillance and set guidelines for control measures.